Quince Therapeutics(QNCX)

Search documents
Quince Therapeutics(QNCX) - 2020 Q1 - Quarterly Report
2020-05-12 20:16
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR (Exact Name of Registrant as Specified in its Charter) Delaware 90-1024039 ( State or other jurisdiction of incorporation or organization) 269 East Grand Ave. South San Francisco, California 94080 (Address of principal executive offices) (Zip Code) (I.R.S. Employer Identification ...
Quince Therapeutics(QNCX) - 2019 Q4 - Annual Report
2020-03-16 20:16
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38890 Cortexyme, Inc. (Exact name of registrant as specified in its Charter) Delaware 90-1024039 (State or other jurisdiction of inco ...
Quince Therapeutics(QNCX) - 2019 Q3 - Quarterly Report
2019-11-12 21:45
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________ to _______________ Commission File Number: 001-38890 Cortexyme, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 90-10 ...
Quince Therapeutics(QNCX) - 2019 Q2 - Quarterly Report
2019-08-09 20:12
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________ to _______________ Commission File Number: 001-38890 Cortexyme, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 90-1024039 ...
Quince Therapeutics(QNCX) - 2019 Q1 - Quarterly Report
2019-06-12 20:19
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________ to _______________ Commission File Number: 001-38890 Cortexyme, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 90-102403 ...